| scholarly article | Q13442814 |
| P2093 | author name string | Yok-Lam Kwong | |
| Wai-Hung Yuen | |||
| Annie Pang | |||
| Eric W C Tse | |||
| Jordy Leung | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 740-746 | |
| P577 | publication date | 2006-09-12 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells | |
| P478 | volume | 109 |
| Q41084369 | AQP9-induced cell cycle arrest is associated with RAS activation and improves chemotherapy treatment efficacy in colorectal cancer. |
| Q39022539 | ATP-binding cassette transporter A1 (ABCA1) promotes arsenic tolerance in human cells by reducing cellular arsenic accumulation |
| Q37486703 | Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. |
| Q83464821 | Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery |
| Q37310939 | Aquaglyceroporins and metalloid transport: implications in human diseases |
| Q37649779 | Aquaglyceroporins: generalized metalloid channels |
| Q37351562 | Aquaporin water channels in mammals |
| Q35866055 | Arsenic and antimony transporters in eukaryotes |
| Q58793896 | Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells |
| Q37999067 | Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease |
| Q37145891 | Arsenic-based antineoplastic drugs and their mechanisms of action |
| Q38877924 | Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9 |
| Q64999959 | Braving the Element: Pancreatic β-Cell Dysfunction and Adaptation in Response to Arsenic Exposure. |
| Q37073603 | Cellular transport and homeostasis of essential and nonessential metals |
| Q33746130 | Clinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemia |
| Q43409934 | Comparative Molecular Docking Studies with ABCC1 and Aquaporin 9 in the Arsenite Complex Efflux |
| Q41847628 | Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes |
| Q48200030 | Cytotoxicity of arsenic trioxide in single leukemia cells by time-resolved ICP-MS together with lanthanide tags |
| Q33778338 | Difference in glycerol levels between leukemia and normal bone marrow stem cells |
| Q36534415 | Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia |
| Q39008731 | Effects of aquaporins on chemosensitivity to cisplatin in ovarian cancer cells |
| Q53283532 | Expression of aquaglyceroporins in epithelial ovarian tumours and their clinical significance. |
| Q24605527 | From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia |
| Q37929546 | Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia |
| Q37117735 | Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia |
| Q55265662 | Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis. |
| Q33618916 | Metabolism, toxicity and anticancer activities of arsenic compounds |
| Q37776244 | Metalloid Transport by Aquaglyceroporins: Consequences in the Treatment of Human Diseases |
| Q42715412 | Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells. |
| Q36941941 | New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach |
| Q89542085 | Old dog, new trick: Trivalent arsenic as an immunomodulatory drug |
| Q59808745 | PIN1 in Cell Cycle Control and Cancer |
| Q37982115 | Pathogenesis and treatment of leukemia: an Asian perspective |
| Q34304715 | Pathways of arsenic uptake and efflux. |
| Q52689241 | Prognostic values of aquaporins mRNA expression in human ovarian cancer. |
| Q35728654 | Projection map of aquaporin-9 at 7 A resolution |
| Q47797108 | Quantification of the Intracellular Life Time of Water Molecules to Measure Transport Rates of Human Aquaglyceroporins. |
| Q37354231 | Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice |
| Q37712353 | Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives |
| Q34611982 | Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface |
| Q55356248 | Significance of aquaporins' expression in the prognosis of gastric cancer. |
| Q38522309 | Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. |
| Q89497633 | Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma |
| Q28387708 | Toxicological responses of environmental mixtures: Environmental metal mixtures display synergistic induction of metal-responsive and oxidative stress genes in placental cells |
| Q39185316 | Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species |
Search more.